Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,17
KB3,72
PKN55,5555,591,48
Msft416,59416,670,83
Nokia4,474,640,94
IBM256,6256,71-2,56
Mercedes-Benz Group AG57,7357,751,54
PFE25,9825,99-1,71
06.02.2025 17:59:51
Indexy online
AD Index online
select
AD Index online
 

  • 06.02.2025 17:59:04
Theravance Bioph-WI (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
9,57 -1,54 -0,15 154 908
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 06.02.2025
Popis společnosti
Obecné informace
Název společnostiTheravance Biopharma Inc
TickerTBPH
Kmenové akcie:Ordinary Shares
RICTBPH.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 99
Akcie v oběhu k 08.11.2024 49 174 296
MěnaUSD
Kontaktní informace
UliceUGLAND HOUSE, SOUTH CHURCH STREET
MěstoGEORGE TOWN
PSČKY1-1104
ZeměCayman Islands
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13456 508 086 000

Business Summary: Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Theravance Biopharma Inc revenues increased 14% to $45.6M. Net loss decreased 12% to $40.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - bal decrease of 42% to $15.1M (expense), Selling, general and administrative -bal decrease of 7% to $38.8M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 06.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerRick Winningham64
Chief Financial Officer, Senior Vice PresidentAziz Sawaf42
Senior Vice President, General Counsel, SecretaryBrett Grimaud50
Senior Vice President - Commercial and Medical Affairs, Chief Business OfficerRhonda Farnum59
Senior Vice President - Development and Head of Ireland OfficeAine Miller47